UNION, FDA

UNION therapeutics Denmark

10.01.2023 - 16:53:32

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa

FDA's Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by moderate to severe hidradenitis suppurativa (HS)HS is a chronic, progressive, inflammatory, and scarring skin disease leading to a diminished quality of life, for which very limited treatment options existOrismilast is a high-potency PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of psoriasis and atopic dermatitis (AD), for which a Fast Track designation has also been granted in ADView original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa-301718014.html

@ prnewswire.co.uk